Seegene, 69,604 Shares Net Sold by Foreigners in Last 5 Days... Stock Price at 248,000 KRW (+2.56%)
As of 12:30 PM on the 26th, Seegene is trading at 248,000 KRW, up 2.56% from the previous day. The trading volume is 1,312,898 shares, which is 95.73% of the previous day's volume. Seegene is known as a company that develops, manufactures, and sells molecular diagnostic reagents.
On August 25th, Minjeong Seon, a researcher at Hana Financial Investment, stated, "Especially after vaccine development, it is increasingly likely that the COVID-19 virus will not suddenly disappear but remain as a seasonal respiratory disease, so Seegene's sales are expected to maintain a scale of 200 to 300 billion KRW. Ultimately, as the COVID-19 virus continues to occur, the significantly increased sales scale of Seegene is expected to be not a one-time event in 2020 but a mid- to long-term event lasting at least three years." She set Seegene's target price at 280,000 KRW.
Over the past five days, individual investors have net purchased 43,236 shares of Seegene, while foreigners and institutions have net sold 69,604 shares and net purchased 19,062 shares, respectively.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③

※Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.